The application of highsensitivity creactive protein in. It is an acutephase protein of hepatic origin that increases following interleukin6 secretion by macrophages and t cells. Retrieved july 1, in this trial of apparently healthy persons jupitfr hyperlipidemia but with elevated highsensitivity creactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. High sensitivity creactive protein hscrp boston heart. C reactive protein crp is a biomarker of inflammation. In this trial, 17,802 healthy men and women with lowdensity lipoprotein cholesterol levels of less than mg per deciliter and high sensitivity c reactive protein levels of 2. Although subjects were selected based on both an elevated hscrp level and a normal ldl cholesterol level, the trial did not include a group. Crp can be elevated with inflammatory conditions ra, lupus, ibd, sores, etc. Rosuvastatin to prevent vascular events in men and women. High sensitivity c reactive protein hs crp levels are associated with cardiovascular risk and have been proposed as a target for therapeutic intervention. Previous statin primary prevention studies included patients at higher risk than those studied in the jupiter trial.
In this trial, 17,802 healthy men and women with lowdensity lipoprotein cholesterol levels of less than mg per deciliter and highsensitivity creactive protein levels of 2. The limitations of measuring hs crp it is important to remember that both crp and hs crp become elevated in a wide range of acute and chronic inflammatory conditions such as infections, rheumatic. C reactive protein crp is an acutephase reactant and has high intraindividual variability. In this trial, 17,802 healthy men and women with lowdensity lipoprotein cholesterol levels of less than mg per deciliter and highsensitivity c reactive protein levels of 2. Estimates of treatment effectiveness were based on the jupiter trial and were varied in sensitivity analyses. Perque potent c guard as effective as statins at lowering. The jupiter study justification for the use of statins in prevention.
Lowrisk older patients 50 years and older with raised high. Trial design offers only limited indirect information about role of hscrp. Researchers tested the hypothesis that patients with elevated blood levels of the inflammationmarker c reactive protein. Independent effects of ldl cholesterol and hscrp lowering in. Rosuvastatin, inflammation, creactive protein, jupiter. Its physiological role is to bind to lysophosphatidylcholine expressed on the surface of dead or. In the recently completed justification for use of statins in prevention. In this trial of apparently healthy persons without hyperlipidemia but with elevated high sensitivity c reactive protein levels, rosuvastatin significantly reduced. Jul 19, 2019 the trial was sponsored by astrazenecathe marketer of crestor rosuvastatin. Rosuvastatin, creactive protein, ldl cholesterol, and the jupiter. The trial focused on patients with normal lowdensity lipoprotein ldl cholesterol levels but increased levels of high sensitivity c reactive protein hs crp. Clinical relevance of high sensitivity creactive protein in. Rosuvastatin to prevent vascular events in men and women with elevated c reactive protein.
Highsensitivity creactive protein, obesity, and subclinical. Considering that the jupiter trial included persons with a very low ldlc, hs crp should be costeffective in this subset regardless of which statin is used if the targets of ldlc. Reduction in creactive protein and ldl cholesterol and cardiovascular event rates after initiation of rosuvastatin. Third report of the national cholesterol education program ncep. Until then, hs crp is a risk marker that may be useful. Highsensitivity creactive protein and cardiovascular disease. The implications of expanding treatment recommendations based on these results have not been evaluated. Although data regarding the association of hs crp with cv disease is extensive and consistent, its role in clinical practice remains unclear. Since statins lower levels of highsensitivity creactive protein as well. High sensitivity crp hs crp is more precise than standard crp when measuring baseline ie, normal concentrations and enables a measure of chronic inflammation. Jupiter trial overview rosuvastatin vs placebo for primary. The fundamental role of inflammation in the pathogenesis of atherothrombotic disease is based upon strong evidence and is wellaccepted. Reduction in c reactive protein and ldl cholesterol and cardiovascular event rates after initiation of rosuvastatin. Jan 29, 2011 much controversy surrounds the use of highsensitivity creactive protein hs crp as a marker of cardiovascular cv risk.
Newer cv risk stratification strategies incorporating hs crp e. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults adult treatment panel iii. Apr 23, 2009 in the 2008 industrysupported jupiter trial jw gen med nov 18 2008, healthy people with normal ldl cholesterol levels jupiter trial may indicate that hs crp levels can be helpful for selecting individuals who may benefit from statin therapy. Justification for the use of statins in primary prevention. A high sensitivity c reactive protein hs crp test measures low levels of crp and may be used to help evaluate an individual for risk of cardiovascular disease cvd. Rosuvastatin vs placebo for primary prevention in lowmoderate risk older adults with normal ldl, hscrp. Nor did it test hs crp as a screening tool to target treatment, which would have required a parallel arm of subjects who had not been tested for hs crp and were treated without regard to hs crp level. After 12 months of rosuvastatin 20mg, ldl cholesterol had fallen by 50% from 108 to 55mgdl and the median hs crp was reduced by 37% from 4. While aspirin does not reduce crp levels, people with elevated crp levels gain more riskreduction benefit from aspirin than those with normal crp levels. Patients were eligible if they had no history of cardiovascular disease, an ldlc of less than 3. Relation of c reactive protein and coronary heart disease in the mrfit nested casecontrol study. Certainly, current guidelines will need to be reassessed based on the jupiter study results. Jupiter ovmc landmark trials series ridker pm, et al.
Results among patients with ldl mgdl and hs crp levels 2. Jul 02, 2019 consistent effects were observed in all subgroups evaluated. Jupiter was a randomized doubleblind placebocontrolled study investigating the use of rosuvastatin in the primary prevention of cardiovascular disease. To discuss the use of high sensitivity c reactive protein hscrp as a screening tool for cardiovascular risk. An intervention trial evaluating rosuvastatin jupiter. The jupiter trial compared rosuvastatin to placebo and found that statin reduced ldl cholesterol concentration by 50%, crp concentration by 37% and cardiovascular event rate by 44%. Creactive protein crp is an annular ringshaped, pentameric protein found in blood plasma, whose circulating concentrations rise in response to inflammation. Therefore, a single test for high sensitivity crp hs crp may not reflect an individual patients basal hs crp level. An intervention trial evaluating rosuvastatin jupiter1 trial, which was conducted with 17 802 primaryprevention patients with ldl cholesterol concentrations implications from the jupiter trial in primary prevention, measurement of traditional risk factors is considered a useful first step in determining those at. Data support that high sensitivity c reactive protein hs crp may be such an independent marker. The trial focused on patients with normal lowdensity lipoprotein ldl cholesterol levels but increased levels of highsensitivity creactive protein hs crp. Crp should not be measured for initiation of statins during times of known.
The jupiter trial justification for the use of statins in prevention. Should we measure creactive protein on earth or just on. An intervention trial evaluating rosuvastatin jupiter trial2 has generatednewinterestin thismarker and provoked considerabledebate about the potential role. In the strictest interpretation, the jupiter trial expands the potential. Because half of all vascular events occur in jupitter with normal or low levels of ldl cholesterol, jupiter was designed to determine whether hs crp testing could identify these juupiter.
To discuss the use of high sensitivity c reactive protein hs crp as a screening tool for cardiovascular risk. Primary results of the jupiter trial, demonstrating the efficacy of statin therapy in reducing first major cardiovascular events among patients with low levels of ldlc, but increased levels of highsensitivity creactive protein. Within the jupiter trial, where all participants had an hscrp of 2 mgl, statin therapy reduced vascular event rates by 40%, even in the subgroup with native ldlc high sensitivity crp hscrp and its role in pathogenesis, prognosis and prevention of cvd. Jupiter justification for the use of statins in primary prevention. Jupiter a primary prevention trial 10 sought to evaluate the utility of a statin in reducing major adverse cardiovascular events in patients with normal to low cholesterol levels ldlc high hscrp levels 2 mgl. Multiple studies have demonstrated that elevated levels of highsensitivity creactive protein hs crp are associated with increased cardiovascular cv risk. A total of 17,802 apparently healthy men and women were randomized to receive either rosuvastatin 20 mg or placebo. Jupiter demonstrates that statins are effective for primary prevention of cardiovascular. Plasma crp concentrations increase rapidly and dramatically 100fold or more in response to tissue injury or inflammation.
Rosuvastatin, inflammation, creactive protein, jupiter, and. Rosuvastatin to prevent vascular events in men and women with. The results of the jupiter trial may indicate that hs crp levels can be helpful for selecting individuals who may benefit from statin therapy. Aims to assess the prognostic importance of high sensitive c reactive protein hscrp in patients with mild to moderate aortic valve stenosis during placebo or simvastatinezetimibe treatment in simvastatin and ezetimibe in aortic stenosis seas. Thus, debate is ongoing regarding the clinical value of various emerging biomarkers, including c reactive protein crp measured with high sensitivity methods hscrp.
Relation of creactive protein and coronary heart disease in the mrfit nested casecontrol study. Clinical trials related to cardiology clinical trials sponsored by jupitef statins. Major studies have found that the level of crp in the body predicts future risk of. A randomized trial of rosuvastatin in the prevention. Hdl cholesterol was unchanged when the trial was stopped, but triglycerides were lowered by. Paul ridker, eleanor danielson, francisco fonseca, jacques genest, antonio gotto, john kastelein, wolfgang. Repeat measurement may be required to firmly establish an individuals basal hs crp concentration. Apr 01, 2010 in the recently completed justification for use of statins in prevention. Jupiter enrolled apparently healthy men aged 50 years and older and women aged 60 years and older who had an ldl level less than mgdl, a high sensitivity crp level of 2. Jupiter multinational randomized double blind placebo controlled trial of rosuvastatin in the prevention of cardiovascular events among individuals with low ldl and elevated hscrp ridker et al nejm 2008. An intervention trial evaluating rosuvastatin jupiter 1 trial, which was conducted with 17 802 primaryprevention patients with ldl cholesterol concentrations high sensitivity c reactive protein hscrp concentrations.
Nov 18, 2019 thus, debate is ongoing regarding the clinical value of various emerging biomarkers, including creactive protein crp measured with highsensitivity methods hscrp. The jupiter trial is widely hailed as a landmark trial that has the potential to dramatically change the landscape of primary prevention of cardiovascular disease. Background the jupiter trial found that rosuvastatin reduces vascular events in apparently healthy subjects with elevated highsensitivity creactive protein hs crp but normal lowdensity lipoprotein ldl cholesterol levels. Justification for the use of statins in prevention. Retrieved july 1, in this trial of apparently healthy persons jupitfr hyperlipidemia but with elevated high sensitivity c reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. Among emerging biomarkers, one of the largest databases exists for hscrp, the classical acutephase protein. Perque potent c guard as effective as statins at lowering hscrp. How useful is highsensitivity crp as a risk factor for. The role of creactive protein as a risk predictor of.
Men with an hscrp 2mgdl in the physicians health study had a 50% reduction in myocardial infarction. C reactive protein crp is an annular ringshaped, pentameric protein found in blood plasma, whose circulating concentrations rise in response to inflammation. The jupiter trial is a prospective, placebocontrolled trial evaluating cardiovascular events with statin therapy in primary prevention patients with ldl values hs crp values 2 mgl. Intramural research program, national institute of arthritis and musculoskeletal and skin diseases, national institutes of health.
The jupiter trial was stopped early at the recommendation of its independent data and safety monitoring board after a median followup of 1. Rosuvastatin, creactive protein, ldl cholesterol, and the. The american heart association aha recently published a scientific statement regarding criteria for evaluation of novel markers. Hs crp is the analyte of choice for cardiovascular risk assessment, due to superior assay precision, accuracy, availability, and the existence of standards for proper calibration when compared to other acutephase reactants. What should you do when your creactive protein crp. The jupiter trial was designed to assess whether apparently healthy persons with levels of lowdensity lipoprotein ldl that do not mandate statin treatment, as per current guidelines high sensitivity c reactive protein hs crp. The jupiter justification for the use of statins in prevention. Inflammation, risk prediction, and the prevention of ascvd. Oct 19, 2009 individuals with increased hscrp may also benefit from lowdose aspirin therapy. However, patients with crp jun 01, 2019 the trial focused on patients with normal lowdensity lipoprotein ldl cholesterol levels but increased levels of highsensitivity creactive protein hs crp. A total of 17,802 apparently healthy men and women were randomized to receive either rosuvastatin. Assessment of hscrp levels in clinical practice is feasible and inexpensive. Jupiter was the first clinical trial to indicate that statin.
Methods and results in 1620 seas patients, we measured lipids and hscrp at baseline and after 1 year. Hs crp is a class iib indication for screening with the main indication the intermediaterisk group for deciding statin therapy. Overall, the results of jupiter trial are consistent with the notion that achieving very low levels of lowdensity lipoprotein cholesterol and hs crp can enhance the benefits of statin therapy in the primary prevention of cvd. The costeffectiveness of creactive protein testing and. First, by its intentional and illadvised exclusion of patients with low levels of high sensitivity creactive protein hscrp, it is not possible to assess whether. However, the results of jupiter trial raise some important questions about the primary prevention of cvd.
To explain the implications of expanded inclusion criteria for primary prevention based on the jupiter trial results. The trial focused on patients with normal lowdensity lipoprotein ldl cholesterol levels but increased levels of highsensitivity c reactive protein hs crp. However, the jupiter trial did not target specific concentrations of hscrp or ldl cholesterol by means of a strategy of titration of rosuvastatin. Highsensitivity crp hs crp is more precise than standard crp when measuring baseline ie, normal concentrations and enables a measure of chronic inflammation. Researchers found very important effects of lowering crp in people who had high levels to begin with. Jupiter was a primaryprevention statin study, in which elevated levels of hs crp were used for the first time as a selection criterion. The jupiter trial was designed to assess whether apparently healthy persons with levels of lowdensity lipoprotein ldl that do not mandate statin treatment, as per current guidelines hs crp test measures low levels of crp and may be used to help evaluate an individual for risk of cardiovascular disease cvd. Rosuvastatin, c reactive protein, ldl cholesterol, and the jupiter trial in the jupiter trial april 4, p 1175,1 paul ridker and colleagues enrolled apparently healthy men and women who were regarded as being at increased vascular risk because of raised concentrations of c reactive protein crp. Also, the jupiter trial showed definitively that in patients with high crp levels but normal cholesterol levels, crestor significantly and substantially reduced cardiovascular risk. The trial was sponsored by astrazenecathe marketer of crestor rosuvastatin. Jupiter was the first clinical trial to indicate that statin therapy may provide benefit to patients with lowtonormal ldl levels and no known cardiovascular disease. The new england journal of medicine 2196 n engl j med 359.
183 27 721 1177 257 387 742 365 1002 418 504 1467 1408 479 648 1069 1457 327 1082 784 1450 840 770 1416 19 1456 1032 1279 1366 654 1116